Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Kamada-API · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Kamada-API | DRUG | - |
Inclusion Criteria: 1. Signed informed consent. 2. "At-risk" alleles associated with serum AAT \< 11 μM including null alleles and deficiency alleles. This must be documented in the subject's history or laboratory tests performed at screening. 3. At least 18 years of age. 4. Evidence of lung diseas...
Kamada-API is used for the treatment of Alpha 1-Antitrypsin Deficiency, a rare genetic condition that can lead to lung and liver damage. It is an investigational therapy being developed by Kamada Ltd. and is currently in Phase 2 clinical development.
Kamada-API is being developed by Kamada Ltd., a biopharmaceutical company. The company's stock is traded under the ticker symbol KMDA. The drug is an investigational small molecule intended for patients with Alpha 1-Antitrypsin Deficiency.
Kamada-API is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase II/III study of the drug has been completed, but it remains in clinical development for Alpha 1-Antitrypsin Deficiency.
Kamada-API has been studied in a completed clinical trial with the identifier NCT00460096. This was a Phase II/III study that enrolled 50 participants with Alpha 1-Antitrypsin Deficiency in the United States. The trial was randomized and double-blind, though it did not use a control group.
Kamada-API is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Alpha 1-Antitrypsin Deficiency. A Phase II/III clinical trial has been completed, but the drug has not yet received regulatory approval.